Details

Autor(en) / Beteiligte

• Drinkard, Bart E., MSPT
• Keyser, Randall E., PhD
• Paul, Scott M., MD
• Arena, Ross, PhD, PT
• Plehn, Jonathan F., MD
• Yanovski, Jack A., MD, PhD
• Di Prospero, Nicholas A., MD, PhD

Titel

Exercise Capacity and Idebenone Intervention in Children and Adolescents With Friedreich Ataxia

Ist Teil von

• Archives of physical medicine and rehabilitation, 2010-07, Vol.91 (7), p.1044-1050

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Drinkard BE, Keyser RE, Paul SM, Arena R, Plehn JF, Yanovski JA, Di Prospero NA. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Objective To determine the exercise capacity of children and adolescents with Friedreich's Ataxia (FA) and to evaluate the effects of 6 months of idebenone treatment on exercise capacity. Design Exploratory endpoint in a randomized double-blind, placebo-controlled, phase II clinical trial designed to investigate the effects of idebenone on a biomarker of oxidative stress. Setting Exercise physiology laboratory in a single clinical research center. Participants Ambulatory subjects (N=48; age range, 9–17y) with genetically confirmed FA. Intervention Idebenone administered orally 3 times a day for a total daily dose of approximately 5, 15, and 45mg/kg or matching placebo for 6 months. Main Outcome Measures Peak oxygen consumption per unit time (peak VO2 ) and peak work rate (WR) were measured during incremental exercise testing at baseline and after treatment. Echocardiography and neurologic assessments were also completed before and after treatment. Results Baseline mean peak VO2 ± SD was 746±246mL/min (16.2±5.8mL/kg/min), and WR was 40±23W for all subjects. Peak VO2 and WR were correlated with short guanine-adenine-adenine allele length and neurologic function. Relative left ventricular wall thickness was increased but left ventricular ejection fraction was normal in most subjects; there was no relationship between any exercise and echocardiographic measures. There were no significant changes in mean peak VO2 or WR after idebenone treatment at any dose level relative to placebo. Conclusions Exercise capacity in children and adolescents with FA was significantly impaired. The basis for the impairment appears to be multifactorial and correlated to the degree of neurologic impairment. Although idebenone has previously been shown potentially to improve features of FA, idebenone treatment did not increase exercise capacity relative to placebo.